Neurogenesis Hypothesis and Phase 2A Clinical Trials of NA-831 for the Treatment of Alzheimer's Disease

Neurogenesis Hypothesis and Phase 2A Clinical Trials of NA-831 for the Treatment of Alzheimer's Disease

The hippocampus continues to generate new neurons throughout life, a process is known as adult hippocampal neurogenesis (AHN). There was a marked and progressive decline of DCX+ cell numbers in AD patients as compared with neurologically healthy individuals. AHN impairment compromises hippocampal fu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of biomedical science 2023-12, Vol.19 (4)
Hauptverfasser: Tran, Lloyd L., Vu, Fern D., Tran, Zung V.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 4
container_start_page
container_title International journal of biomedical science
container_volume 19
creator Tran, Lloyd L.
Vu, Fern D.
Tran, Zung V.
description The hippocampus continues to generate new neurons throughout life, a process is known as adult hippocampal neurogenesis (AHN). There was a marked and progressive decline of DCX+ cell numbers in AD patients as compared with neurologically healthy individuals. AHN impairment compromises hippocampal function in AD and MCI. This indicates that reduced AHN causes memory impairments and cognitive deterioration in the disease. It was observed that AHN impairment take place prior to the presence of senile plaques and neurofibrillary tangles (NFTs) in the dentate gyrus. Thus, stimulating inherent AHN could serve as a therapeutic target for improving cognitive function and promoting synaptic resilience.
doi_str_mv 10.59566/iabs.2023.p045
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_59566_iabs_2023_p045</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_59566_iabs_2023_p045</sourcerecordid><originalsourceid>FETCH-crossref_primary_10_59566_iabs_2023_p0453</originalsourceid><addsrcrecordid>eNqVj7FuwjAURS1UJGhhZn0bU8KzgwOMEW3FhDqwWwZeiFESR35hgK9vEvUHOt0rXZ0rHSEWEmO902m6cvbMsUKVxA2u9UhMpdY6UluJb0PHaLdBNRHvzHdEnSqppuJ2pEfwN6qJHcPh2fi2GKqtr_BTWCZQGexLV7uLLeEUnC0ZfA7HLNomEnIfoCO6gWxbUd32W1a-CnIVhSXDp2PqXmZinHckzf_yQ6y-v077Q3QJnjlQbprgKhueRqIZfEzvY3of0_sk_yd-ATRBVBg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Neurogenesis Hypothesis and Phase 2A Clinical Trials of NA-831 for the Treatment of Alzheimer's Disease</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Tran, Lloyd L. ; Vu, Fern D. ; Tran, Zung V.</creator><creatorcontrib>Tran, Lloyd L. ; Vu, Fern D. ; Tran, Zung V. ; Biomed Industries, Inc</creatorcontrib><description>The hippocampus continues to generate new neurons throughout life, a process is known as adult hippocampal neurogenesis (AHN). There was a marked and progressive decline of DCX+ cell numbers in AD patients as compared with neurologically healthy individuals. AHN impairment compromises hippocampal function in AD and MCI. This indicates that reduced AHN causes memory impairments and cognitive deterioration in the disease. It was observed that AHN impairment take place prior to the presence of senile plaques and neurofibrillary tangles (NFTs) in the dentate gyrus. Thus, stimulating inherent AHN could serve as a therapeutic target for improving cognitive function and promoting synaptic resilience.</description><identifier>ISSN: 1550-9702</identifier><identifier>EISSN: 1555-2810</identifier><identifier>DOI: 10.59566/iabs.2023.p045</identifier><language>eng</language><ispartof>International journal of biomedical science, 2023-12, Vol.19 (4)</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids></links><search><creatorcontrib>Tran, Lloyd L.</creatorcontrib><creatorcontrib>Vu, Fern D.</creatorcontrib><creatorcontrib>Tran, Zung V.</creatorcontrib><creatorcontrib>Biomed Industries, Inc</creatorcontrib><title>Neurogenesis Hypothesis and Phase 2A Clinical Trials of NA-831 for the Treatment of Alzheimer's Disease</title><title>International journal of biomedical science</title><description>The hippocampus continues to generate new neurons throughout life, a process is known as adult hippocampal neurogenesis (AHN). There was a marked and progressive decline of DCX+ cell numbers in AD patients as compared with neurologically healthy individuals. AHN impairment compromises hippocampal function in AD and MCI. This indicates that reduced AHN causes memory impairments and cognitive deterioration in the disease. It was observed that AHN impairment take place prior to the presence of senile plaques and neurofibrillary tangles (NFTs) in the dentate gyrus. Thus, stimulating inherent AHN could serve as a therapeutic target for improving cognitive function and promoting synaptic resilience.</description><issn>1550-9702</issn><issn>1555-2810</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqVj7FuwjAURS1UJGhhZn0bU8KzgwOMEW3FhDqwWwZeiFESR35hgK9vEvUHOt0rXZ0rHSEWEmO902m6cvbMsUKVxA2u9UhMpdY6UluJb0PHaLdBNRHvzHdEnSqppuJ2pEfwN6qJHcPh2fi2GKqtr_BTWCZQGexLV7uLLeEUnC0ZfA7HLNomEnIfoCO6gWxbUd32W1a-CnIVhSXDp2PqXmZinHckzf_yQ6y-v077Q3QJnjlQbprgKhueRqIZfEzvY3of0_sk_yd-ATRBVBg</recordid><startdate>20231215</startdate><enddate>20231215</enddate><creator>Tran, Lloyd L.</creator><creator>Vu, Fern D.</creator><creator>Tran, Zung V.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20231215</creationdate><title>Neurogenesis Hypothesis and Phase 2A Clinical Trials of NA-831 for the Treatment of Alzheimer's Disease</title><author>Tran, Lloyd L. ; Vu, Fern D. ; Tran, Zung V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-crossref_primary_10_59566_iabs_2023_p0453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Tran, Lloyd L.</creatorcontrib><creatorcontrib>Vu, Fern D.</creatorcontrib><creatorcontrib>Tran, Zung V.</creatorcontrib><creatorcontrib>Biomed Industries, Inc</creatorcontrib><collection>CrossRef</collection><jtitle>International journal of biomedical science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tran, Lloyd L.</au><au>Vu, Fern D.</au><au>Tran, Zung V.</au><aucorp>Biomed Industries, Inc</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neurogenesis Hypothesis and Phase 2A Clinical Trials of NA-831 for the Treatment of Alzheimer's Disease</atitle><jtitle>International journal of biomedical science</jtitle><date>2023-12-15</date><risdate>2023</risdate><volume>19</volume><issue>4</issue><issn>1550-9702</issn><eissn>1555-2810</eissn><abstract>The hippocampus continues to generate new neurons throughout life, a process is known as adult hippocampal neurogenesis (AHN). There was a marked and progressive decline of DCX+ cell numbers in AD patients as compared with neurologically healthy individuals. AHN impairment compromises hippocampal function in AD and MCI. This indicates that reduced AHN causes memory impairments and cognitive deterioration in the disease. It was observed that AHN impairment take place prior to the presence of senile plaques and neurofibrillary tangles (NFTs) in the dentate gyrus. Thus, stimulating inherent AHN could serve as a therapeutic target for improving cognitive function and promoting synaptic resilience.</abstract><doi>10.59566/iabs.2023.p045</doi></addata></record>
fulltext fulltext
identifier ISSN: 1550-9702
ispartof International journal of biomedical science, 2023-12, Vol.19 (4)
issn 1550-9702
1555-2810
language eng
recordid cdi_crossref_primary_10_59566_iabs_2023_p045
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
title Neurogenesis Hypothesis and Phase 2A Clinical Trials of NA-831 for the Treatment of Alzheimer's Disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T01%3A41%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neurogenesis%20Hypothesis%20and%20Phase%202A%20Clinical%20Trials%20of%20NA-831%20for%20the%20Treatment%20of%20Alzheimer's%20Disease&rft.jtitle=International%20journal%20of%20biomedical%20science&rft.au=Tran,%20Lloyd%20L.&rft.aucorp=Biomed%20Industries,%20Inc&rft.date=2023-12-15&rft.volume=19&rft.issue=4&rft.issn=1550-9702&rft.eissn=1555-2810&rft_id=info:doi/10.59566/iabs.2023.p045&rft_dat=%3Ccrossref%3E10_59566_iabs_2023_p045%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true